VanEck Biotech ETF
BBH
110 hedge funds and large institutions have $152M invested in VanEck Biotech ETF in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 31 reducing their positions, and 9 closing their positions.
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 111 → 110 (-1)
4.05% less ownership
Funds ownership: 37.62% → 33.56% (-4.1%)
16% less capital invested
Capital invested by funds: $180M → $152M (-$28.5M)
39% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VWM
Valley Wealth Managers
Paramus,
New Jersey
|
+$3.03M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.17M |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$892K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$840K |
| 5 |
FFP
FourThought Financial Partners
Venice,
Florida
|
+$631K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$9.93M |
| 2 |
TIA
Traphagen Investment Advisors
Oradell,
New Jersey
|
-$9.21M |
| 3 |
MJRIC
Mogy Joel R Investment Counsel
Beverly Hills,
California
|
-$5.76M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.8M |
| 5 |
JP Morgan Chase
New York
|
-$1.17M |
BBH Hedge Fund Activity: Q3 2023 in Review
110 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q3 2023, worth a combined $152M — down 16% from $180M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new BBH positions and 9 closed out — a net gain of 2 holders — while 19 added to existing stakes and 31 trimmed.
The largest buyer was Valley Wealth Managers, opening a new position worth an estimated $3.03M. The largest seller was Qube Research & Technologies (QRT), cutting an estimated $9.93M.
- 110 institutional investors held VanEck Biotech ETF (BBH) as of Q3 2023, down from 111 in Q2 2023.
- Funds reported $152M of VanEck Biotech ETF stock for Q3 2023, down 16% quarter-over-quarter.
- 11 funds opened new VanEck Biotech ETF positions in Q3 2023 and 9 closed out, a net change of +2 holders.
- The largest VanEck Biotech ETF buyer in Q3 2023 was Valley Wealth Managers, an estimated $3.03M added.
- The largest VanEck Biotech ETF seller in Q3 2023 was Qube Research & Technologies (QRT), an estimated $9.93M sold.
Based on aggregated 13F filings for Q3 2023.